PT  - JOURNAL ARTICLE
ED  - , 
TI  - Another KRAS Inhibitor Holds Its Own
AID  - 10.1158/2159-8290.CD-NB2020-098
DP  - 2020 Oct 28
TA  - Cancer Discovery
4099  - http://cancerdiscovery.aacrjournals.org/content/early/2020/10/28/2159-8290.CD-NB2020-098.short
4100  - http://cancerdiscovery.aacrjournals.org/content/early/2020/10/28/2159-8290.CD-NB2020-098.full
AB  - According to the KRYSTAL-1 study, the KRASG12c inhibitor adagrasib, also known as MRTX849, is largely well tolerated and shows considerable efficacy in patients with non–small cell lung cancer harboring this mutation. The drug is also active, albeit more modestly, in colorectal cancer and several other solid tumor types.